Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine:: Formulation development and in vivo assessment

被引:97
作者
Chen, Ying [1 ]
Li, Gao [2 ]
Wu, Xianggen [2 ]
Chen, Zhiyu [3 ]
Hang, Jiangeng [2 ]
Qin, Bei [1 ]
Chen, Song [2 ]
Wang, Ruihua [2 ]
机构
[1] Wuhan Gen Hosp, Dept Pharm, Wuhan 430070, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan 430030, Peoples R China
[3] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92092 USA
关键词
vinpocetine; self-microemulsifying drug delivery system; formulation design; in vivo rerlease; in situ absorption from intestine; bioavailability;
D O I
10.1248/bpb.31.118
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A new self-microemulsifying drug delivery system (SMEDDS) has been developed to increase the solubility, dissolution rate and oral bioavailability of vinpocetine (VIP), a poor water-soluble drug. The formulations of VIP-SMEDDS were optimized by solubility assay, compatibility tests, and pseudo-ternary phase diagrams analysis. The optimal ratio in the formulation of SMEDDS was found to be Labrafac:oleic acid: Cremophor EL: Transcutol P=40: 10:40: 10 (w/w). The average particle diameter of VIP was less than 50 nm. In vitro dissolution study indicated that the dialysis method in reverse was better than the ultrafiltration method and the dialysis method in simulating the drug in vivo environment. Comparing with VIP crude drug power and commercial tablets, (-)VIP-SMEDDS caused a 3.4- and 2.9-fold increase in the percent of accumulated dissolution at 3 h. Further study on the absorption property of VIP-SMEDDS employing in situ intestine of rats demonstrated that VIP in SMEDDS could be well-absorbed in general intestinal tract without specific absorption sites. In addition, the developed SMEDDS formulations significantly improved the oral bioavailability of VIP in rats. Relative bioavailability of (-)VIP-SMEDDS and (+)VIP-SMEDDS increased by 1.85- and 1.91-fold, respectively, in relative of VIP crude powder suspension. The mechanisms of enhanced bioavailability of VIP might contribute to the improved release, enhanced lymphatic transport, and increased intestinal permeability of the drug.
引用
收藏
页码:118 / 125
页数:8
相关论文
共 39 条
[1]  
ASHINGTON C, 1990, INT J PHARMACEUT, V58, P1
[2]   Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine [J].
Bönöczk, P ;
Gulyás, B ;
Adam-Vizi, V ;
Nemes, A ;
Kárpáti, E ;
Kiss, B ;
Kapás, M ;
Szántay, C ;
Koncz, I ;
Zelles, T ;
Vas, A .
BRAIN RESEARCH BULLETIN, 2000, 53 (03) :245-254
[3]   COMPARATIVE EFFECTS OF VINPOCETINE AND 8-BR-CYCLIC GMP ON THE CONTRACTION AND CA-45-FLUXES IN THE RABBIT AORTA [J].
CHIU, PJS ;
TETZLOFF, G ;
AHN, HS ;
SYBERTZ, EJ .
AMERICAN JOURNAL OF HYPERTENSION, 1988, 1 (03) :262-268
[4]   LIPID MICROEMULSIONS FOR IMPROVING DRUG DISSOLUTION AND ORAL ABSORPTION - PHYSICAL AND BIOPHARMACEUTICAL ASPECTS [J].
CONSTANTINIDES, PP .
PHARMACEUTICAL RESEARCH, 1995, 12 (11) :1561-1572
[5]   AN INVESTIGATION INTO THE MECHANISMS OF SELF-EMULSIFICATION USING PARTICLE-SIZE ANALYSIS AND LOW-FREQUENCY DIELECTRIC-SPECTROSCOPY [J].
CRAIG, DQM ;
BARKER, SA ;
BANNING, D ;
BOOTH, SW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 114 (01) :103-110
[6]  
Gershanik T, 1996, Pharm Dev Technol, V1, P147, DOI 10.3109/10837459609029889
[7]   Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity [J].
Gershanik, T ;
Haltner, E ;
Lehr, CM ;
Benita, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 211 (1-2) :29-36
[8]   Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs [J].
Gershanik, T ;
Benita, S .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) :179-188
[9]   Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs [J].
Gursoy, RN ;
Benita, S .
BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (03) :173-182
[10]   Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor [J].
Hauss, DJ ;
Fogal, SE ;
Ficorilli, JV ;
Price, CA ;
Roy, T ;
Jayara, AA ;
Keirns, JJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (02) :164-169